Kalvista Pharmaceuticals (NASDAQ:KALV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The firm presently has a $16.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s target price points to a potential upside of 11.65% from the company’s current price.
According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “
KALV has been the topic of a number of other research reports. ValuEngine raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. BidaskClub upgraded Kalvista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, November 29th. Needham & Company LLC reissued a “buy” rating and set a $35.00 target price on shares of Kalvista Pharmaceuticals in a research note on Tuesday. Finally, Roth Capital set a $30.00 target price on Kalvista Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $29.17.
Kalvista Pharmaceuticals stock traded up $0.21 during mid-day trading on Friday, hitting $14.33. 87,109 shares of the company’s stock were exchanged, compared to its average volume of 139,683. The firm has a market capitalization of $265.80 million, a P/E ratio of -10.38 and a beta of 2.16. Kalvista Pharmaceuticals has a fifty-two week low of $9.86 and a fifty-two week high of $34.92. The company has a quick ratio of 8.29, a current ratio of 8.29 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $12.21 and its 200-day simple moving average is $15.84.
Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Tuesday, December 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.22. Kalvista Pharmaceuticals had a negative return on equity of 22.29% and a negative net margin of 144.64%. The firm had revenue of $3.92 million for the quarter, compared to analyst estimates of $3.23 million. Research analysts expect that Kalvista Pharmaceuticals will post -1.98 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of KALV. FMR LLC acquired a new position in Kalvista Pharmaceuticals during the 1st quarter worth approximately $21,036,000. Strs Ohio bought a new stake in shares of Kalvista Pharmaceuticals in the second quarter worth $68,000. Swiss National Bank bought a new stake in shares of Kalvista Pharmaceuticals in the second quarter worth $390,000. Wells Fargo & Company MN boosted its holdings in Kalvista Pharmaceuticals by 3.2% during the second quarter. Wells Fargo & Company MN now owns 35,710 shares of the specialty pharmaceutical company’s stock worth $791,000 after purchasing an additional 1,103 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Kalvista Pharmaceuticals during the second quarter worth $605,000. 73.00% of the stock is currently owned by institutional investors and hedge funds.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: New Google Finance Tool and Screening Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.